Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prednisone Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

NCT02055820
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Venetoclax, Cyclophosphamide, Obinutuzumab, Rituximab, Doxorubicin, Vincristine, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Santa Maria, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

NCT02924766
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Niraparib, Apalutamide, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
West Hollywood, California • Louisville, Kentucky • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 4 Interventional Results available

Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)

NCT00296296
View directory record Official record
Conditions
Kidney Transplant, Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions
Cyclosporin, Tacrolimus, 'Diabetes Education / Management'
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 11, 2026, 5:57 PM EDT
Recruiting Phase 4 Interventional

Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department

NCT07228052
View directory record Official record
Conditions
Asthma
Interventions
Dexamethasone 16mg IM, Prednisone 60mg PO
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

NCT02849990
View directory record Official record
Conditions
Stage III Prostate Adenocarcinoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Abiraterone Acetate, Apalutamide, Degarelix, Indomethacin, Laboratory Biomarker Analysis, Prednisone
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF

NCT00650091
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
N-acetylcysteine (NAC), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
35 Years to 85 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult Subjects

NCT01711827
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of Isavuconazole, Pharmacokinetics of Prednisolone
Interventions
Isavuconazole, Prednisone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2012 · Synced Sep 11, 2026, 5:57 PM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)

NCT04974996
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Loncastuximab tesirine, Prednisone, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

NCT00774202
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Rituxan, Cyclophosphamide, Vincristine, Prednisone, Higher Dose of Rituximab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
12 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 11, 2026, 5:57 PM EDT
Withdrawn Phase 1 Interventional

Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)

NCT02578511
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma in Complete Remission, Mixed Phenotype Acute Leukemia in Complete Remission
Interventions
Ixazomib
Drug
Lead sponsor
Ehab L Atallah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 2 Interventional

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

NCT00058084
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
ixabepilone, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)

NCT02806947
View directory record Official record
Conditions
Acute GVHD
Interventions
Sirolimus, Prednisone
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
21
States / cities
Duarte, California • Los Angeles, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

NCT00107380
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, tositumomab and iodine I 131 tositumomab
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
78
States / cities
Anchorage, Alaska • Tucson, Arizona • Duarte, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2016 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 3 Interventional

Prednisolone Trial in Children Younger Than 4 Years

NCT03141970
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
Prednisolone
Drug
Lead sponsor
All India Institute of Medical Sciences
Other
Eligibility
1 Year to 4 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Stanford, California • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

NCT00924469
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone, Leuprolide, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Houston, Texas • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

NCT01848067
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Alisertib, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin

NCT00268853
View directory record Official record
Conditions
Diffuse Large-Cell Lymphoma
Interventions
CPOP-R, CHOP-R
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
58
States / cities
Concord, California • Hollister, California • La Jolla, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

NCT01234025
View directory record Official record
Conditions
Castrate-Resistant Prostate Cancer
Interventions
ISIS EIF4E Rx, Prednisone, Docetaxel
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Fayetteville, Arkansas • San Bernardino, California • Fort Collins, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

NCT00657774
View directory record Official record
Conditions
Asthma
Interventions
FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg, Placebo
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
19
States / cities
Phoenix, Arizona • Anaheim, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2008 · Synced Sep 11, 2026, 5:57 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

NCT04497584
View directory record Official record
Conditions
Advanced Squamous Non Small Cell Lung Cancer
Interventions
Afatinib + Prednisone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 11, 2026, 5:57 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
58
States / cities
Fresno, California • San Diego, California • Santa Barbara, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 11, 2026, 5:57 PM EDT
Terminated Phase 1 Interventional

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

NCT00493766
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Boston, Massachusetts • St Louis, Missouri • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 11, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

NCT00815919
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
bortezomib, Prednisone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Sep 11, 2026, 5:57 PM EDT
Withdrawn Phase 1Phase 2 Interventional

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

NCT06329830
View directory record Official record
Conditions
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
177Lu-PSMA-617, Niraparib abiraterone acetate, Prednisone
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 11, 2026, 5:57 PM EDT